Acrux Limited’s FY26 receipts soared 960% to $5 million, fuelled by licensing milestones and growing generic sales, while FDA guidance clears the way for pivotal Phase III trials of its Female Testosterone therapy.
- FY26 customer receipts surged 960% to $5 million
- Received $1.35 million licensing milestone from Gedeon Richter
- Secured $1.6 million institutional funding for Female Testosterone
- FDA clarified Phase III trial pathway for Female Testosterone
- Operating expenses declined year-on-year, cash position strengthened
Revenue Growth Driven by Licensing Milestone and Generics
Acrux Limited (ASX:ACR) reported a striking 960% increase in receipts from customers for FY26, reaching $5.002 million compared to just $0.521 million the previous year. The June quarter alone contributed $1.780 million, buoyed by a $1.35 million milestone payment from Gedeon Richter Plc for licensing the Estradiol spray Lenzetto® in Australia. This upfront payment is part of a broader deal worth up to $4.05 million in future milestones tied to regulatory approval and sales targets, underscoring Acrux’s growing foothold in hormone therapy markets.
FDA Clears Path for Phase III Trials in Female Testosterone
Central to Acrux’s strategy is its Female Testosterone asset, targeting Hypoactive Sexual Distress Disorder (HSDD); a condition affecting millions of women with no approved testosterone therapy in the US or Europe. Following successful Phase I and II trials, the US Food and Drug Administration has provided clear guidance on the Phase III clinical trial program, including feedback on safety, toxicology, and manufacturing. This regulatory clarity is a critical step towards commercialisation and has attracted significant interest from global pharmaceutical companies exploring co-development partnerships.
Institutional Funding Boosts Development Pipeline
To support the advancement of Female Testosterone, Acrux secured $1.6 million in commitments from institutional and sophisticated investors through a share placement. This capital injection strengthens the company’s balance sheet and underpins ongoing clinical and commercial activities. The placement was completed in two tranches during the June quarter, reflecting strong investor confidence in Acrux’s strategic pivot towards women’s health therapeutics.
Topical Generics Provide Stable Cashflow Base
While the spotlight is on Female Testosterone, Acrux’s topical generic portfolio continues to generate steady cashflow, contributing $3.652 million in revenue for FY26. The US licensee, Tru Pharma, reported a rebound in sales of Nitroglycerine 0.4% Ointment after resolving supply issues, alongside growth in Dapsone 7.5% Gel as distribution constraints eased. This reliable revenue stream supports the company’s R&D investment, even as it phases out lower-potential generic projects.
Cost Management and Cash Position
Operating expenditure for the June quarter was $1.529 million, down from $8.825 million in the prior year, reflecting disciplined cost control and a focus on high-value projects. Staff costs remain the largest expense but are being carefully managed. Acrux ended the quarter with $1.705 million in cash and cash equivalents, and combined with available finance facilities, has an estimated nine quarters of funding runway. This financial position provides a solid foundation for the upcoming Phase III trials and potential licensing deals.
Bottom Line?
Acrux’s financial momentum and FDA guidance position its Female Testosterone asset for a critical development phase, but the commercial impact hinges on successful Phase III outcomes and partner agreements.
Questions in the middle?
- How will the timing and design of the Phase III trial influence partner interest and regulatory approval?
- What are the potential financial terms and timelines for co-development or licensing deals in women’s health?
- Can Acrux sustain growth in its generics portfolio while advancing its specialty pharma pipeline?